Pet CD33 Therapeutic Antibody Development

Creative Biolabs specializes in pioneering antibody therapeutics tailored for companion animal health. Our Pet CD33 Therapeutic Antibody Development program focuses on advancing immune-targeted therapies for dogs and cats through precision-engineered monoclonal antibodies. CD33, a sialic acid-binding immunoglobulin-like lectin, plays an important role in regulating innate immune cell activity, particularly in myeloid cell signaling and inflammatory balance. By targeting CD33, we aim to provide novel therapeutic strategies to manage chronic inflammation, immune dysregulation, and hematologic conditions in pets. Creative Biolabs integrates innovation with scientific rigor to help veterinary researchers, pharmaceutical companies, and academic collaborators transform discovery into effective biologics. Contact our experts to explore how CD33-targeting antibody development can strengthen your veterinary R&D pipeline.

Platforms in Therapeutic Antibody Discovery

At Creative Biolabs, we provide a suite of antibody discovery technologies optimized for companion animals, ensuring species-specific accuracy and translational reliability. These complementary discovery systems provide the foundation for robust and flexible development strategies. Whether you are seeking early discovery or preclinical candidate generation, Creative Biolabs delivers end-to-end support.

• Phage Display: Using proprietary canine and feline antibody libraries, we identify CD33-specific binders with high affinity and optimal sequence diversity. This platform allows rapid screening and engineering of antibody leads suitable for therapeutic use in both dogs and cats.
• Single-B Cell Sorting: We isolate individual B cells producing antibodies against CD33, enabling natural antibody discovery directly from immunized or diseased donors. These antibodies can be further engineered for therapeutic enhancement and stability.
• Hybridoma Technology: Our hybridoma platform generates monoclonal antibodies that can undergo downstream engineering, including caninization or felinization, ensuring low immunogenicity and strong in vivo performance.

Comprehensive Antibody Development Services

Our antibody development services are designed to support the full life cycle of veterinary biologic research, from discovery to preclinical validation.

Antibody Characterization

Includes antigen-binding validation, epitope mapping, affinity measurement, and functional activity assays using advanced biophysical and cell-based methods.

Antibody Engineering

Incorporates Fc optimization, stability enhancement, and species-specific sequence adaptation (canine/feline frameworks) to ensure compatibility and therapeutic performance.

Preclinical Evaluation

Comprehensive pharmacodynamic, pharmacokinetic, and immunogenicity assessments, including efficacy testing in relevant companion animal models.

Antibody Development

High-yield expression, purification, and scalable production for research or preclinical-grade materials, supported by cell line development and analytical validation.

Discover How We Can Help - Request a Consultation

Why Focus on CD33?

CD33 (Siglec-3) is a transmembrane receptor expressed primarily on myeloid lineage cells, such as monocytes, macrophages, and some dendritic cells. Functionally, CD33 acts as an inhibitory receptor, modulating immune activation through ITIM-mediated signaling to maintain homeostasis and prevent excessive inflammation. In dogs, aberrant CD33 signaling has been linked to chronic inflammatory diseases and immune cell dysfunction. In cats, research suggests potential relevance to myeloproliferative and immune-mediated disorders. By regulating myeloid cell activation, CD33 presents an attractive therapeutic target for managing both autoimmune and inflammatory diseases in pets, and potentially for oncology indications where immune modulation plays a central role. For veterinary researchers exploring innate immune control or inflammatory disease models, CD33 represents a valuable and underexplored pathway.

Mechanism of Action

Therapeutic antibodies targeting CD33 function by modulating its inhibitory signaling pathway on immune cells. Upon antibody binding, CD33 signaling can be altered, either suppressed or blocked, affecting downstream phosphorylation of ITIM motifs and subsequent recruitment of phosphatases like SHP-1 and SHP-2. This modulation can restore immune balance by reducing hyperactivation in inflammatory diseases or by enhancing immune cell activity in oncology contexts. In companion animals, CD33-directed antibodies may therefore serve dual functions: immunosuppression in chronic inflammatory states or immune activation when combined with immunostimulatory agents. Through rational antibody design and functional assays, Creative Biolabs optimizes CD33 antibodies for the intended mechanism of action and desired immune response.

Fig 1. Peripheral blood morphologic features from a dog with acute myeloid leukemia (AML).¹

Our Advantages

• Species-Specific Expertise: Extensive experience with canine and feline immune system characterization, ensuring accurate translation from discovery to application.
• Advanced Discovery Technologies: Multi-platform approach using phage display, hybridoma, and single-B cell methods tailored for each species.
• Integrated Development Workflow: From antigen design to preclinical evaluation, all steps are performed in-house or through trusted partners, ensuring data continuity and quality.
• Customizable Project Design: Each antibody program is adapted to the client's specific disease model, mechanism of action, and regulatory goals.
• Strong Data Integrity and Confidentiality: All studies are conducted under stringent scientific and ethical standards, maintaining confidentiality and reproducibility.

Partner with Creative Biolabs

Creative Biolabs welcomes collaborations with veterinary pharmaceutical companies, academic research centers, and biotechnology innovators interested in developing CD33-targeted therapies for pets. Our multidisciplinary team provides the infrastructure, expertise, and resources to accelerate antibody discovery, characterization, and preclinical validation for canine and feline diseases.

If your organization is exploring immune-modulating strategies, hematologic disorders, or inflammation-related targets in pets, we invite you to collaborate with Creative Biolabs. Partner with us to bring precision antibody therapeutics closer to improving the health and longevity of companion animals. Connect with our scientific experts today to discuss your CD33 therapeutic antibody project.

Contact Our Team for More Information and to Discuss Your Project.

Reference

1. Stokol, Tracy et al. "Dogs with Acute Myeloid Leukemia Have Clonal Rearrangements in T and B Cell Receptors." Frontiers in veterinary science vol. 4 76. 31 May. 2017. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fvets.2017.00076